FIGURE 3.
Prevalence of (A) gBRCA1 and (B) gBRCA2 mutations by location in the 93 newly diagnosed Japanese ovarian cancer patients from the CHARLOTTE study who were positive for mutations. †Four patients with silent gBRCA1 mutations (exon deletion) are not indicated in the figure; 16 patients with L63X founder mutation are also excluded. BRCA, breast cancer susceptibility gene; OCCR, ovarian cancer cluster region